

Curriculum Vitae

Anthony J. Cmelak, M.D.

STATUS/ ADDRESS: Associate Professor
Vanderbilt Department of Radiation Oncology
B-902, The Vanderbilt Clinic
Nashville, TN 37232-5671
(615) 322-2555 Fax: (615) 343-0161
anthony.cmelak@vanderbilt.edu

Medical Director
Vanderbilt-Ingram Cancer Center at Franklin
2107 Edward Curd Lane
Franklin TN 37067
(615) 591-9890 Fax (615) 591-5899

MEDICAL LICENSE: Tennessee: MD000028099
California: G077690
UPIN G28981
NPI 1912099334

BOARD CERTIFICATION: American Board of Radiology, Radiation Oncology 1/1997

FACULTY APPOINTMENTS: Associate Professor, Dept. Radiation Oncology, VUMC 5/2002-present
Assistant Professor, Dept. Radiation Oncology, VUMC 7/1996-5/2002
Medical Director Radiation Oncology, VUMC 7/1999-6/2003

TRAINING: Chief Resident, Stanford Radiation Oncology 7/1995-6/1996
Residency: Radiation Oncology, Stanford University 7/1993-6/1996
Internship :Internal Medicine,
St. Mary's Medical Center, San Francisco, CA 7/1992-6/1993
M.D.: Northwestern University Medical School 8/1988-5/1992
B.S.: Biological Sciences, University of California at Irvine 1983-1988

APPOINTMENTS AND ADMINISTRATION (COMMUNITY SERVICE):
American Society for Therapeutic Radiology and Oncology 1994-present
Director, Radiation Oncology Head & Neck Program 1996-present
Director, Radiation Oncology Brain Tumor Program 1996-2007
Director, Radiosurgery Program 1996-2007
Eastern Coop Oncology Group, Radiation & HN Committees 1997-present
Radiation Therapy Oncology Group 1997-present
American Society of Clinical Oncology 1998-present
Clinical Protocol Review and Monitoring Committee 1998-present
Radiation Safety Committee 1999-2007
Society of NeuroOncology 1999-present

Medical Director, Vanderbilt University Medical Center	1999-2003
Medical Director, Vanderbilt Ingram Cancer Center Franklin	2002-present
American Academy of Otolaryngology, Head and Neck Surgery	2001-present
NCI Cancer Trials Support Unit	2001-present
VMG Executive Committee	2007-present

HONORS/AWARDS:

South Coast Hospital Medical Scholarship	1983
Deans Honor List, Univ. of California at Irvine	1983-1987
Buckby Medical Scholarship, Sigma Chi Fraternity	1988
Vice President, American Medical Students Associations	1989-1990
Alpha Omega Alpha Nominee, Northwestern Medical School	1992
Chief Resident, Stanford Radiation Oncology	1995-1996
Wilhelm K. Roentgen NCI Award for Research	1996
Co-Director, Bristol Myers Squibb Preceptorship Program	1997-98
ASTRO Travel Grant Award, Lisbon Portugal	2001
Friends of Otolaryngology: "Best Teacher Award"	2006

MEMBERSHIPS:

Phi Rho Sigma Medical Fraternity	1989-1992
Toxicity and Regulatory Review Committee (TARRC)	1998-2000
American Society for Therapeutic Radiology and Oncology, Member (ASTRO)	1994-present
Radiation Therapy Oncology Group (RTOG)	1997-present
Eastern Coop Oncology Group, Radiat & HN Core Committees	1997-present
Clinical Protocol Review and Monitoring Committee (CPRMC)	1998-present
American Society of Clinical Oncology (ASCO)	1998-present
American Academy of Otolaryngology-Head and Neck Surgery	1999-present
Society of NeuroOncology	1999-present
NCI Cancer Trials Support Unit (CTSU)	2001-present
American Brain Tumor Association	2002-present
Tennessee Oncology Practice Society (TOPS)	2006-present

CLINICAL PRIVILEGES:

Vanderbilt Medical Center, Nashville TN
 Veterans Administration Hospital, Nashville TN
 Gateway Medical Center, Clarksville TN
 Maury Regional Hospital, Columbia TN
 Williamson County Medical Center, Franklin TN
 Middle Tennessee Medical Center, Murfreesboro TN

TEACHING:**VANDERBILT MEDICAL EDUCATION (1996-present)****Radiation Oncology Graduate Medical Education****Residents:**

Donnie Stacey 2001-2004	David Yu	2006-present
-------------------------	----------	--------------

Joseph Kaminski 2004-2006	Jerry Jaboin 2006-present
Irene Connelly 2001-2005	Ken Niermann 2006-present
Kim Dong 2002-2006	Eddy ShihYang 2006-present
Fen Xia 2002-2006	Ildiko Csiki 2008
Christopher Willey 2003-2008	
Roberto Diaz 2005-present	

Fellows:

Robert McRae 2000-2001

Vanderbilt Medical Physics

Darryl Kaurin, PhD 2001-2003

Chris Scarfone, PhD 2002-2004

Andy Hauger, PhD 2005-2006

Graduate Students

Albin Gonzalez

COMMUNITY SERVICE:

Canby Robinson Society 2007

Make-A-Wish Foundation 2007

American Cancer Society (L'Ete du Vin) 2000-2008

DEVELOPMENT:**Implementation of new technology**

Intravascular Brachytherapy 1998

Image Fusion 2000

Electronic Portal Imaging 2001

Intensity-Modulated Radiation Therapy 2001

Cone-Beam CT 2004

Stereotactic Lung Radiosurgery 2005

Adaptive Radiotherapy 2006

JOURNAL MANUSCRIPT REVIEWER:

Cancer	2007-present
--------	--------------

Cancer Therapy	2007-present
----------------	--------------

Head and Neck	2007-present
---------------	--------------

CONSULTING:

Amgen, Inc. Consultant (2006-2008)

Bristol-Myers- Squibb Consultant (2004-2008)

Ortho-Biotech Consultant (2004-2007)

Sanofi-Aventis Consultant (2006-2008)

RESEARCH PROJECTS/CLINICAL TRAILS:

Primary Investigator: A Pilot Study of Sunitinib in Combination with Chemoradiation Therapy in Patients with Local-Regionally Recurrent Head and Neck Cancer. Pfizer, Inc. In Preparation.

Co-Primary Investigator: A Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiation with Lower Dose IMRT in Patients with HPV-Positive Resectable Oropharynx Cancer. ECOG Phase II Multi-institutional trial, in development.

Primary Investigator at Vanderbilt: "A Phase II Randomized Trial of Chemoradiation with or without Panitumimab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Protocol 20062080, HN 0765, Amgen, Inc. (\$191,306) 2008

Co-investigator: "Autosegmentation for Head and Neck Radiotherapy Planning." R01 EB006193-01A1 NCI funded study (5% salary support, \$1,491,828) 2007-2010.

Co-investigator: "Radiotherapy Planning via Autosegmented Brain Structures." R21 CA 089657-01A2 NCI funded study. (10% salary support) 2002-2004

Co-investigator: "X-ray Guided Drug Delivery Systems by Apcitide." R21 CA89999-01 NCI funded study (10% salary support) 2001-2003

Primary Investigator at Vanderbilt: HN 0031 "A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy. (5% salary support) Intrabiotics, Inc.

Primary Investigator: All RTOG studies at Vanderbilt University Medical Center. (3% salary support)

Primary Investigator: "A Phase II Trial of Chemoradiation for Organ Preservation in Locally-Advanced Resectable Squamous Cell Carcinoma of the Larynx and Oropharynx." ECOG 2399 Multi-Institution Phase II Trial.

Co-Investigator: Alternating Intensive Chemotherapy and Hyperfractionated Radiotherapy Supported by Peripheral Blood Stem Cells for High Risk Malignant Gliomas of Childhood." Phase I/II Study VU PBT-III at Vanderbilt University.

Co-Investigator: NEU 9843, "Phase III Randomized Trial of Gadolinium Texaphyrine Injection (PCI-0120) as a Radiation Sensitizer in Patients Receiving Whole Brain Radiation Therapy for the Treatment of Brain Metastases." (5% salary support) Pharmacyclics, Inc.

Primary Investigator: VU HN 9955, "A Phase II Trial of Radiation with Concomitant Taxotere in High Risk Postoperative Patients with Squamous Cell Carcinoma of the Head and Neck." (5% salary support) Aventis, Inc.

Co-Investigator: VU 9926, "A Phase II Study of Recombinant Human Keratinocyte Growth Factor (rHuKGF) in Head and Neck Cancer Patients Receiving Concurrent Chemotherapy with Standard Radiation Therapy." (3% salary support) Amgen, Inc.

Co-investigator: VU 9916, "A Randomized Phase III Multicenter Trial of Neoadjuvant Docetaxel (Taxotere®) Plus Cisplatin and 5-Fluorouracil (TPF) versus Neoadjuvant Cisplatin Plus 5-Fluorouracil

Followed by Concomitant Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” (3% salary support) Aventis, Inc.

Co-Investigator: “The Efficacy of Computerized Photon Knife Radiotherapy in the Management of Cushing’s Disease.” Investigator-initiated study of patients treated at Vanderbilt University.

Primary Investigator: “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Doses of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Head and Neck Cancers.” (5% salary support)

Co-Investigator: A Phase II Study of Temazolamide, Thalidomide, and Radiation Therapy for Patients with Brain Metastasis from Malignant Melanoma. A cytokine Working Group Trial. A Multi-Institutional Trial supported by Schering Plough.

Co-Investigator: “A Phase II Study of CPT-11 and Cisplatin for Incurable Cancer of the Head and Neck.” A VICCAN Multi-Institutional Trial.

Primary Investigator: “A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine Hydrochloride 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Oral Mucositis.” (3% salary support) McNeil Pharmaceuticals.

FUNDING:

Co-Investigator: R01 EB006193-01A1 (NCI sponsored) Autosegmentation for Head and Neck Radiotherapy Planning. 4.4% effort (4 yrs, \$1,491,828) 2007-2010

Vanderbilt PI: VU HN 0282, McNeil Consumer and Specialty Pharmaceuticals
5% effort (2 yrs, \$202,478) 2003-2004

Co-Investigator: R21 CA-089657-01A2 (NCI sponsored)
10% effort (2yrs, \$225,742) 2002-2003

Co-Investigator: R21 PA-98-008 (NIH sponsored)
10% effort (2 yrs, \$289,427) 2001-2002

Vanderbilt PI: VU HN 0031 Intrabiotics, Inc. Mucositis Protection Phase III study
5% effort (1 yr, \$95,996) 2000-2001

Primary Investigator: ECOG 2399: A Phase II trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx. Speech and Swallowing Correlatives - sponsored by BMS. (\$100,000). 1999-2004

Vanderbilt Co-Investigator: VU 9916 Pharmacia Corp. KGF Mucositis Phase III
3% effort (2 yrs, \$132,539) 2000-2001

Vanderbilt PI: VU 9926 HN Phase III chemoradiation 3% effort (2 yrs, \$56,000)	2000-2001
Primary Investigator: VU HN 9955 High Risk RT/Taxotere Phase II 5% effort (2 yrs, \$186,881)	2000-2002
Vanderbilt PI: NEU 9843 Pharmacyclics, Inc. Gadtex/RT Brain Metastases Phase III 5% effort (2 yrs, \$154,076)	2000-2001
Vanderbilt PI: HN 0112, Daiichi Corp. Cevimeline Phase III for Xerostomia 5% effort (1 yr, \$70,000)	2001-2002
Vanderbilt PI: all RTOG studies at Vanderbilt 2-3% effort (6 yrs, approx \$25,000 total salary support)	1996-2002
Co-Director: Bristol Myers Squibb Preceptorship Program 5% effort (3 yrs, \$75,000)	1997-1999
Vanderbilt Co Investigator: START Trial (Intravascular Brachytherapy), Novoste Corp. 3% effort (1 yr, \$3,900 salary)	1999
Vanderbilt Co-Investigator: Beta-Cath Trial, Novoste Corp. Intravascular Brachytherapy 3% effort (1 yr, \$3,900 salary)	1999

PEER REVIEWED MANUSCRIPTS:

1. **Cmelak AJ**; Cox R; Adler J; Fee W; Goffinet DR. "Radiosurgery for Skull-Base Recurrences and Nasopharyngeal Carcinoma." International Journal of Radiation Oncology, Biology, Physics. 37(5): p. 997-1003, 1997.
2. **Cmelak, AJ**; Kapp, DS. "Long-term Survival with Whole Abdominopelvic Irradiation in Platinum-Refractory Ovarian Cancer." Gynecologic Oncology 65: 453-60, 1997.
3. Demanes DJ; Rodriguez RR; Hsu ICJ; **Cmelak AJ**; Brachytherapy - Oncological Seminars on Locoregional Therapy (Vol 2). New York: Zuckschwerdt, 1997.
4. Wantanabe N; De Rosa SC; **Cmelak AJ**; Hoppe RT; Herzenberg LA; Roederer, M; and Herzenberg, LA. "Long-Term Depletion of Naive T Cells in Patients Treated for Hodgkins Disease." Blood 90(9): p 3662-3672, 1997.
5. **Cmelak AJ**; Murphy BA, Day T. "Combined Modality Therapy for Locoregionally Advanced Head and Neck Cancer." Oncology 13(10 Suppl 5): p. 83-91, 1999.
6. **Cmelak, AJ**; Choy H; Shyr Y; Mohr P; Glantz MJ; Johnson DH: "National Survey on Prophylactic Cranial Irradiation: Differences in Practice Patterns Between Medical and Radiation Oncologists." Int. J. Rad Oncol Biol Phys, 44(1), p.157-162, 1999.

7. Choy H, Shyr Y, **Cmelak AJ**, Mohr P, Johnson DH. "Patterns of Practice Survey for Non-Small Cell Lung Cancer in the U.S. Cancer 88(6):1336-1346, 2000.
8. Hallahan, DE, Chen A, Teng M, **Cmelak AJ**. Drug-Induced Interactions in Tumor Blood Vessels. Oncology 13(10 Suppl 5): p. 71-7, 1999.
9. Hallahan D, Geng L, **Cmelak A**, Chakravarthy BA, Scarfone C, Gonzalez A. Targeting Drug Delivery to Radiation-Induced Neoantigens in Tumor Microvasculature. Control Release 74(1-3): 183-191, 2001.
10. Demanes, DJ; Samaranayake, RP; Rodriguez, RR; **Cmelak A**; Cruz, RM. LDR Brachytherapy and External Radiation for Carcinoma of the Base of Tongue: Implantation of the Primary Tumor and Cervical Adenopathy. Journal of Brachytherapy Oct/Dec, p. 211-14, 2000.
11. **Cmelak AJ**; Abou-Khalil B; Konrad PE; Duggan D; Maciunas RJ. Stereotactic Radiosurgery for Medically-Intractable Mesial Temporal Lobe Epilepsy: A Case Report. Seizure. 2001 Sep 10(6):442-6.
12. Murphy BA, **Cmelak AJ**, Burkey B, Netterville J, Shyr Y, Douglas S, Smith W. Topoisomerase I Inhibitors in the Treatment of Head and Neck Cancer. Oncology 15 (7): Suppl 8, 47-52, 2001.
13. Schefter JK, Allen G, **Cmelak AJ**, Johnson M, Toms S, Duggan D, Blevins LS. The Utility of External Beam Irradiation and Intracystic ³²P Radiation in the Treatment of Craniopharyngiomas. Journal of Neuro-Oncology 56: 69-78, 2002.
14. Hallahan DE, Qu S, Geng L, **Cmelak A**, Chakravarthy A, Martin W, Scarfone C, Gioglio T. Radiation-Mediated Control of Drug Delivery. Am J Clin Oncol 24(5): 473-80, 2001.
15. Robbins KT, Kumar P, Harris J, McCullough T, **Cmelak A**, Sofferman R, Weisman R, Wilson W, Weymuller E, Fu K. Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV–T4 Head and Neck Squamous Cell Carcinoma is Feasible and Efficacious in a Multi-Institutional Setting: Initial Results of a Radiation Therapy Oncology Group Trial 9615. The Journal of Clinical Oncology Mar 1; 23(7):1447-54, 2005.
16. Jennings MT, Cartwright J, **Cmelak A**, Helton KJ, Johnson MD, Maciunas R, Martincic D, Moots P, Pais R, Shyr Y, Tulipan N, Whitlock JA. Differential Responsiveness to 'High Risk' Pediatric Brain Tumors to Dose-Intensive Induction Chemotherapy and Hyperfractionated Radiotherapy. Pediatric Blood Cancer July 43(1): 46-54, 2004.
17. Jennings MT, **Cmelak A**, Johnson MD, Malik S, Moots PL, Pais R, Shyr Y. Dosage Escalation Study of Topotecan in Combination Chemotherapy for High Risk Pediatric Brain Cancers. Pediatr Blood Cancer 43(1):46-54, 2004.
18. Scarfone C; Lavelly WC; **Cmelak AJ**, Delbeke D; Martin W; Billheimer D; Hallahan DE. Prospective Feasibility Trial of Radiotherapy Target Definition for Head and Neck Cancer Using 3-Dimensional PET and CT Imaging. J Nucl Med 45:543-552, 2004.

19. Trotti A; Garden A; Warde P; Symons P; Langer C; Redman R; Pajak T; Fleming T; Henke M; Bourhis J; Rosenthal D; Junor E; **Cmelak A**; Sheehan F; Pulliam J; Devitt-Risse P; Fuchs H; Ang K; A Multinational, Randomized Phase III Trial of Isegenan HCL Oral Solution for Producing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy. Int J Rad Oncol Biol Phys 58(3):674-681, 2004.
20. Lavelly WC, Scarfone C, Cevikalp H, Li R, Byrne DW, **Cmelak AJ**, Price RR, Hallahan DE, Fitzpatrick JM. Phantom Validation of Coregistration of PET and CT for Image-Guided Radiotherapy. Medical Physics 31(5):1083-1092, 2004.
21. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, **Cmelak AJ**, Rotman M, Machtay M, Chao KSC, Schultz CJ, Lee N, Fu KK. Postoperative Concurrent Chemotherapy and Radiation Therapy in High-Risk Squamous Cell Carcinoma of the Head and Neck. NEJM pp. 1936-1944, May 6, 2004.
22. Lavelly WC, Scarfone C, Cevikalp H, Li R, Byrne DW, **Cmelak AJ**, Dawant B, Price RR, Hallahan DE, Fitzpatrick M. Coregistration of PET and CT for Intensity-Modulated Radiotherapy: Clinical Applications. Medical Physics May 34(5):1082-1092, 2004.
23. Devin JK, **Cmelak AJ**, Duggan DM, Allen GS, Blevins LS. The Efficacy of Computerized Photon Knife Radiosurgery in the Management of Patients with Cushing's Disease. Stereo Funct Neurosurg 82:254-262, 2004.
24. Scarfone C, Lavelly WC, **Cmelak AJ**, Delbeke D, Martin WH, Billheimer D, Hallahan DE. Quantification of Molecular and Anatomical Target Contours of Head and Neck Cancer to Facilitate Image-Guided Therapy During IMRT. Int J Radiat Oncol Biol Phys 57(2 Suppl):S300-1, 2004.
25. **Cmelak AJ**, Barbara A. Murphy BA, Burkey B, Douglas S, Netterville J. Taxane-Based Chemoradiation for Organ Preservation with Locally-Advanced Head and Neck Cancer: Results of a Phase II Multi-Institutional Trial. Head Neck Jan 24, 2006.
26. Willey C, Murphy BA, Raben D, Kane M, Weng E, Burkey B, Kish B, Song J, Netterville J, **Cmelak AJ**. Early Results of a Phase II Multi-Institutional Trial of Chemoradiation (CR) Using Weekly Docetaxel (Doc) and Erythropoetin (Epo) for High-Risk Postoperative Head and Neck Cancer (HRPHNC) Patients. Int J Rad Oncol Biol Phys 2007 Apr 1;67(5):1323-31.
27. Robert J.C. Slebos, Yajun Yi, Kim Ely, Jesse Carter, Amy Evjen, Xueqiong Zhang, Yu Shyr, Barbara M. Murphy, **Cmelak AJ**, Brian B. Burkey, James L. Netterville, Shawn Levy, Wendell G. Yarbrough, Christine H. Chung. Gene expression profile associated with HPV in head and neck squamous cell carcinoma. Clin Cancer Res 12(3):701-709, 2006.
28. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation A, **Cmelak AJ**, Levy S, J. Slebos RJ, Yarbrough WG. Gene Expression Profiles Identify Epithelial to Mesenchymal Transition and Nuclear Factor- κ B signaling Deregulation are Important Characteristics of Head and Neck Squamous Cell Carcinoma With a High-Risk of Recurrence Based on Gene Expression Profiles. Cancer Res 66(16): Aug 15;66(16):8210-8218, 2006.

29. Chung CH, Ely K, Varella-Garcia M, McGavran L, Parker J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, Burkey BB, Sinard R, **Cmelak A**, Levy S, Yarbrough WG, Slebos RJC, Hirsch FR. Increased Epidermal Growth Factor Gene Copy Number Is Associated With Worse Prognosis in Head and Neck Squamous Cell Carcinomas. J Clin Oncol. 2006 Sep 1;24(25):4170-6.
30. Murphy BA, **Cmelak A**. Chemoradiation Therapy: The Evolving Role in Head and Neck Cancer and Its Application to Oral Cavity Tumors. Oral Maxillofacial Surg Clin of N Am 18 (4):605-614, 2006.
31. **Cmelak AJ**, Murphy, BA, Burkey B, Douglas S, Netterville J. Taxane-Based Chemoradiation for Organ Preservation with Locally-Advanced Head and Neck Cancer: Results of a Phase II Trial. Head Neck. 2007 Apr;29(4):315-24.
32. **Cmelak AJ**, Li S, Murphy B, Burkey B, Adams GL, Cannon M, Pinto H, Rosenthal DI, Ridge JA, Forastiere AA. Locally Advanced Resectable Larynx (L) or Oropharynx (OP) Cancer: Results of Phase II Organ Preservation Trial E2399. J Clin Oncol. 2007 Sep 1;25(25):3971-7.
33. Machtay M, Pajak T, Suntharalingam M, Shenouda G, Harris J, Hershock D, Stripp D, **Cmelak A**, Schulsinger A, Fu K. Radiotherapy with or without Erythropoietin for Anemic Patients with Head and Neck Cancer: A Randomized Trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 69(4):1068-1017, 2007.
34. Ding GX, Duggan DM, Coffey CW, Hallahan DE, Malcolm A, **Cmelak A**, Deeley M. A Study on Adaptive IMRT Treatment Planning Using kV Cone-Beam CT. Radiother Oncol. 2007 Aug 17.
35. Ding GX, Duggan DM, Newton J, Lu B, Hallahan DE, **Cmelak AJ**, Malcolm A, Coffey CW. Impact of Inhomogeneity Corrections on Dose Coverage in the Treatment of Lung Cancer Using Stereotactic Body Radiation Therapy. Med Phys 34(7): 2985-94, 2007.
36. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounnova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Racz LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio RC, Venkatesan V, Romanov I, Agarwala R, Harter KW, Dugan M, **Cmelak A**, Markoe A, Read PW, Steinbrenner L, Colevas AD, Norris CM, Haddad RI. A Phase III Trial of Docetaxel, Cisplatin, and 5-Fluorouracil versus Cisplatin and 5-Fluorouracil Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. N Engl J Med. 2007 Oct 25;357(17):1705-15.
37. Murphy BA, Gilbert J, **Cmelak A**, Ridner S. Symptom Control Issues and Supportive Care for Patients With Head and Neck Cancers. Clinical Advances in Hem & Oncol 5(10): 807-822, Oct, 2007.
38. Fakhry C, Westra W, Li S, **Cmelak A**, Adams G, Pinto H, Arlene Forastiere, Gillison M. Improved Survival of Patients with Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial. J Natl Cancer Inst. 2008 Feb 12.
39. Gilbert J, **Cmelak A**, Shyr Y, Netterville J, Burkey B, Chung CH, Sinard R, Yarbrough W, Murphy, BA. Phase II Trial of Irinotecan Plus Cisplatin in Patients with Recurrent or Metastatic Squamous Carcinoma of the Head and Neck. Cancer. 2008 Jul 1;113(1):186-92.

40. Dryzmala R, Wasserman TH, Won M, Shaw E, **Cmelak AJ**, Loeffler J, Souhami L. A Phase Ib Trial of the Radiosensitizer: Etanidazole (SR-2508) with Radiosurgery for the Treatment of Recurrent Previously Irradiated Primary Brain Tumors or Brain Metastases (RTOG Protocol #95-02). Radiother Oncol. 2008 Apr;87(1):89-92.
41. Kusuma S, **Cmelak AJ**, Burkey B. Synovial Cell Sarcoma of the Orbit. Manuscript accepted for publication 1/08 to Ears, Nose, and Throat.
42. Floyd JR, Russell PT, **Cmelak A**, Weaver K. Endoscopic, Transnasal Instillation of P-32 for Recurrent Infrachiasmatic Cystic Craniopharyngioma. Submitted to Minimally Invasive Neurosurgery 7/06.
43. Ridner S, Silver H, Gilbert J, Chung C, **Cmelak A**, Burkey B, Yarborough W, Sinard R, Netterville J. Reliability and Validity of the Vanderbilt Head and Neck Symptom Survey: A Tool to Assess Symptom Burden in Patients Treated with Chemoradiation. Submitted for publication.
44. Stacy D, Murphy BA, Duggan D, Netterville J, Burkey BB, Stinson S, **Cmelak AJ**. Induction Chemotherapy and concurrent Chemoradiation Followed by a Radiosurgery Boost for Locally Advanced Nasopharyngeal Carcinoma. Submitted 10/07 to Head Neck.
45. Diaz R, Barbara A. Murphy BA, Burkey B, Netterville J, **Cmelak AJ**. ChemoIMRT for Locally-Advanced Cancers of the Head and Neck. In preparation.
46. Diaz R, Barbara A. Murphy BA, Burkey B, Netterville J, **Cmelak AJ**. Thyroid Storm Induced by Head and Neck ChemoIMRT: A Case Report. Submitted 7/08 to The Oncologist.
47. Diaz R, **Cmelak AJ**. Need for Neck Dissection and Adjuvant Therapy for Head and Neck Cancer in the Modern Era of Chemoradiation Using IMRT. In preparation.
48. **Cmelak AJ**, Lordick F; Borner M, Goldberg RM, Saif MW. The US and the EU perspective: Clinical Manifestation, Diagnosis, Grading, and Management of IRs in Clinical Trials and Beyond. Submitted to Oncology 7/08.

NON-PEER REVIEWED MANUSCRIPTS:

1. Demanes DJ; Rodriguez RR; Hsu ICJ; Altieri G; Hoffman J; Ewing T; **Cmelak AJ**; Eulau SM. "HDR Remote Afterloading Gynecological Template Interstitial Brachytherapy: Rationale, Indications, and Technique." Activity Nov. 8, 1996.
2. Murphy BA, Wells N, **Cmelak A**, Burkey B, Netterville J, Chin J, Dowling E, Smith K, Neuman M, Friedman J. Assessment of Late Effects of Chemoradiation on Swallowing and Nutrition. Advances in Head and Neck Cancer, Dec 2003, pp. 14-18, Vol 2, No 1, 2003.

3. The Oral Mucositis Working Group (Bruce S, Quinn A, Cmelak A). Oral Mucositis Algorithm. US Oncological Disease, 2007

PEER REVIEWED ABSTRACTS:

1. **Cmelak AJ**, Tewari S: "The Properties of Brain RNA (nRNA) Restriction Process." Abstract published in Journal of Neurochemistry, 1987 Supplement.

2. **Cmelak AJ**, Richard MD, Cox S, Adler JR, Fee W, Goffinet DR. Radiosurgery for Skull Base Malignancies and Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 32(1), p194, 1995.

3. **Cmelak AJ**, Cox RS, Kapp DS. Long Term Survival With Whole Abdominopelvic Irradiation (WAI) in Platinum-Refractory Ovarian Cancer. Int J Radiat Oncol Biol Phys 36(1): suppl 1, p176, 1996.

4. Moots PL, Jennings MT, Bowen MG, Choy H, **Cmelak AJ**, Porter LL, Strupp JA, Rosenblatt PA, Cobbs TW, Cohen BH, Gilbert MR: "Multiagent Chemotherapy Followed by Craniospinal Radiation (CSRT) for Adults with Poor Risk Medulloblastoma (MBL) and Ependymoma with Subarachnoid Dissemination (D.E.)." 1998 AAN Scientific Program Abstract E4397.

5. Shyr Y, Choy H, **Cmelak AJ**, Mohr P, Johnson DH: "Pattern of Practice Survey: Non-Small Cell Lung Cancer (NSCLC) in the US." Proc. ASCO #1778, JCO 1998.

6. **Cmelak AJ**, Choy H, Shyr Y, Mohr P, Glantz M, Johnson DH: "Prophylactic Cranial Irradiation: Practice Patterns in the United States." Proc. ASCO #1828, JCO 1998.

7. Dang TP, Murphy BA, **Cmelak AJ**, Netteville J, Burkey B, Day T, Smith W, Wakefield G, Larson T, Smith M: "Carboplatin and Taxol as Induction Therapy for Locally Advanced Carcinoma of the Head and Neck." Proc. ASCO #1516, JCO 1998.

8. **Cmelak, AJ**, Mohr P, Choy H, Shyr Y, Johnson D: "Prophylactic Cranial Irradiation: Treating the patient or the Physician?" Proc. ASTRO abstr #2222, Int J Rad Oncol Biol Phys 42(1), Suppl. 1998.

9. Dang TP, Murphy BA, **Cmelak AJ**, Douglas S., Netteville J, Burkey B, Day T, Larson T, and Smith M. "Induction Chemotherapy with Carboplatin and Paclitaxel Followed by Cisplatin and Weekly Paclitaxel for Stage III/IV Squamous Cell Carcinoma of the Head and Neck." Proc ASCO abstr #1548, JCO 1999.

10. Murphy BA, Douglas S, Dang TP, **Cmelak AJ**, Netteville J, Burkey B, Day T, Smith M, Larson T. "Phase II Trial of Irinotecan (CPT-11) In Metastatic Or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCHN)." J Clin Oncol Proc ASCO (#1578) May 1999.

11. **Cmelak AJ**, Choy H, Murphy BA, Devore R, Burkey B, Day T, LaPorte K, Johnson DH. "Phase I Study of JM-216 With Concurrent Radiation In Non-Small Cell Lung Cancer and Squamous Cell Head and Neck Cancer." J Clin Oncol Proc ASCO May 18, 1999 (#1520), poster presentation.

12. Glantz M, Choy H, Chakravarthy A, **Cmelak AJ**, Curran W, Porter LL, Rosenblatt PA, Moots P, Laporte K, Shyr Y, Johnson DH. "A Randomized Phase III Trial of Concurrent Paclitaxel and Whole Brain

Radiotherapy (WBRT/PAC) vs. WBRT Alone for Brain Metastases. J Clin Oncol Proc ASCO #535, 1999, oral presentation.

13. Shyr Y, Choy H, Mohr P, **Cmelak AJ**, Johnson DH. “International Patterns of Practice Survey: Non-Small Cell Lung Cancer.” Proc ASCO JCO May 1999 (abstr# 1843).

14. Wasserman T, Scott C, Shaw E, Dryzmala R, **Cmelak AJ**, Movsas B, Souhami L. “A Phase II Trial of the Radiosensitizer Etanidazole (SR-2508) with Radiosurgery for the Treatment of Primary Brain Tumors or Brain Metastases (RTOG Protocol #95-02). Int J Rad Oncol Biol Phys Suppl 1999.

15. Mehta MP, Meyers CA, Renschler MF, Eisenberg PD, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, Arwood D, **Cmelak AJ**, Rao A, Brereton H, Timmerman RD, Phan SC, DeVault AR, Curran WJ, Gaspar L. Clinical trial of Gadolinium Texaphyrine (“XCYTRIN”) in patients with brain metastases. Int J Rad Oncol Biol Phys 45(3): Abstract #2082, 1999.

16. **Cmelak AJ**, Abou-Khalil B, Konrad PE, Duggan DM, Maciunas RJ. Stereotactic Radiosurgery for Medically-Intractable Mesial Temporal Lobe Epilepsy. Radiology Suppl 213:p. 238, Abstr #603, 1999, oral presentation.

17. Douglas S, Murphy B, Smith W, Lambert B, Burkey B, **Cmelak AJ**, Netterville J. Loss of Function with Chemoradiation is Followed by Return Toward Baseline at Three Months. Abstr #PA101, 5th Int. Conf. on Head and Neck Cancer, San Francisco, 2000.

18. Murphy BA, **Cmelak A**, Burkey B, Netterville J, Douglas S. A Comparison of Cisplatin (C)/Paclitaxel (P) Versus Carboplatin (CB)/Paclitaxel with Concomitant Radiation (RT). Abstr #PA229, 5th Int. Conf. on Head and Neck Cancer, San Francisco, 2000.

19. Murphy BA, Douglas S, **Cmelak AJ**, Netterville J, Burkey B, Larson T. Phase II Trial of Irinotecan (CPT-11) in Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN). Abstr #166, Fifth International Conference on Head and Neck Cancer, San Francisco, 2000.

20. Mehta MP, Meyers CA, Curran WJ, Schultz CJ, Ford JM, Roa WH, Leibenhaut M, **Cmelak AJ**, Rao A, Timmerman RD, Gaspar L, Phan SC, Eber D, Renschler MF. XCYTRIN (motexafin gadolinium) and Whole Brain Radiation for Patients with Brain Metastases: Lead-in Phase to Randomized Trial – Final Results. Int J Radiat Oncol Biol Phys 48(3): Proc ASTRO abstr # 184, p. 204, IJROBP 2000.

21. Forouzannia A, Sze G, Mehta M, Schultz CJ, Ford JM, Leibenhaut M, Rao A, Cmelak AJ, Timmerman RD. Brain Metastases Regress Isometrically Following Radiation therapy allowing the Use of 1D W.H.O. RECIST Criteria for Adequate Response Evaluation. Int J Rad Oncol Biol Phys 51(3), p250, 2001.

22. Sze G; Mehta M; Schultz CJ, Ford JM, Roa WH, Leibenhaut M, **Cmelak AJ**, Rao A; Timmerman RD, Gaspar L; Curran WJ, Phan SC, DeVault A, Renschler MF Radiologic Response Evaluation of Brain Metastases: Uni-Dimensional (1D) W.H.O. Recist vs. W.H.O. Recist vs. Bi-Dimensional (2d) or 3-Dimensional (3D) Criteria.. Proc ASCO #234, 59a, JCO 2001.

23. Kumar P, Robbins KT, McCulloch T, **Cmelak A**, Sofferman R, Levine P. Intra-Arterial (IA) Cisplatin (P) and Radiation (RT) is Feasible in a Multi-Institutional Setting for the Treatment of Stage IV-T4 Head/Neck Squamous Cell Carcinoma (SCCA): Initial Results of Radiation Therapy Oncology Group (RTOG) Trial 9615. J Clin Oncol Proc. ASCO #918, 230a, 2001.
24. Demanes DJ, Quackenbush J, Schour L, **Cmelak A**, Rodriguez RR. HDR Brachytherapy for Stage III and IV Base of Tongue Carcinoma. American Brachytherapy Society, 2001.
25. Carpenter J, Murphy B, **Cmelak A**, Burkey B, Netterville J, Lamar R. Symptoms associated with chemoradiation therapy (CRT) for locally advanced head and neck cancer. J Clin Oncol Proc ASCO #932, 234a, JCO 2001, oral presentation.
26. Dowling E, Murphy B, **Cmelak A**, Burkey B, Netterville J, Douglas S, Dickson N. Swallowing Deficits in Patients Treated with Combined Chemoradiation (CRT) for locally Advanced Head and Neck cancer (HNC). Proc ASCO #907, 277a, JCO 2001.
27. **Cmelak A**; Choy H; Shyr Y; Mohr P; Glantz MJ; Johnson DH: National Survey on Prophylactic Cranial Irradiation: Differences in Practice Patterns Between Medical and Radiation Oncologists. Year Book of Oncology, E. Glatstein (ed). Mosby-Year Book, Inc., 2001.
28. Hallahan D, Chakravarthy AB, **Cmelak A**, Qu S, Geng L, Martin L, Scarfone C. Recombinant Bacteriophage Capsid Proteins Target Radiation-Inducible Neoantigens. Proc ASCO #1048, 263a, JCO 2001.
29. **Cmelak AJ**, Murphy BA, Burkey B, Bayles S, Netterville J. Recombinant Human Erythropoietin (r-HuEPO) Corrects Anemia and Prevents Transfusion During Induction and Concurrent Chemotherapy During Head and Neck Cancer (HNC) Treatment. ECCO 11 abstr# M-1076, 2001.
30. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, **Cmelak A**, Rotman M, Machtay M, Ensley JF, Chao KSC, Schultz CJ, Lee N, Fu KK. Postoperative Concurrent Radiochemotherapy in High-Risk SCCA of the Head and Neck: Initial Report of RTOG 9501/Intergroup Phase III Trial. J Clin Oncol Proc ASCO #903, 226a, 2002.
31. Murphy BA, Friedman J, Dowling E, Cheatham R, **Cmelak A**. Dietary intake adaptations in head and neck cancer patients treated with chemo radiation. **J Clin Oncol Proc** ASCO #932, p234a, 2002.
32. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, **Cmelak AJ**, Rotman M, Machtay M, Ensley JF, Chao KSC, Schultz CJ, Lee N, Fu KK. Patterns of Failure for Resected Advanced Head & Neck Cancer Treated By Concurrent Chemotherapy and Radiation Therapy: An Analysis of RTOG 9501. Int J Radiat Oncol Biol Phys 54(2); Proc ASTRO, 2002.
33. Warde P, Garden A, Langer C, Symonds P, Trotti A, Fleming T, Redman R, Henke M, Bourhis J, Rosenthal DI, Junor E, **Cmelak A**, Sheehan F, Ang K on behalf of the PROMRT-RT study Investigators. A Randomized Phase III Trial Evaluation the Efficacy of Iseganan HC1 Oral Solution in Decreasing the Incidence and Severity of Ulcerative Oral Mucositis Secondary to Radiation Therapy. Canadian Radiation Oncology Society Meeting 2002.

34. Henke M, Bourhis J, Garden A, Warde P, Langer C, Symonds P, Trotti A, Fleming T, Redman R, Rosenthal D I, Junor E, **Cmelak A**, Sheehan F, Ang K, on behalf of the PROMPT-RT Study Investigators. A Phase III Study Evaluating Isegran HCI Oral Solution in Decreasing the Incidence and Severity of Ulcerative Oral Mucositis in Patients Receiving Radiotherapy or Chemoradiotherapy for Head and Neck Cancer. Green Journal ESTRO Abstract 2002.
35. Kusuma S, **Cmelak AJ**, Burkey B. Synovial Cell Sarcoma of the Medial Canthal Region: A Case Report and Review of the Literature. ACRO 2003 abstract.
36. **Cmelak AJ**, Murphy, BA, Burkey B, Douglas S, Netteville J. Induction Chemotherapy (IC) followed by Concurrent Chemoradiation (CCR) in Locally-Advanced Squamous Head and Neck Cancer (SHNC): Results of a Phase II Trial. J Clin Oncol Proc ASCO 32016, p. 501, 2003.
37. Murphy BA, Smith KA, Dowling E, **Cmelak A**, Burkey B, Forastiere A. Baseline Swallowing Function for Patients on E2399: A phase II Trial of Function Preservation With Induction Paclitaxel/Carboplatin Followed by Radiation Plus Weekly Paclitaxel. J Clin Oncol Proc ASCO #2005, p. 498, 2003.
38. Reine TP, Murphy BA, Bhatt P, **Cmelak A**, Burkey B, Netteville J. Results of a Pilot Survey to Assess Supportive Care Needs in Head and Neck Cancer (HNC) Patients. J Clin Oncol Proc ASCO #2006, p. 498, 2003.
39. D'Haese PF, Duay V, Li R, Aloys du Bois d' Aische, Merchant TE, **AJ Cmelak**, Donnelly E, Niermann KJ, Macq B, Dawant BM. Automatic Segmentation of Brain Structures for Radiation Therapy Planning. SPIE conference, San Diego 2003.
40. **Cmelak AJ**, Chakravarthy A, Hallahan D. Peptide-Guided Drug Delivery to Radiation-Induced Targets in Tumor Blood Vessels. Int J Radiat Oncol Biol Phys Proc ASTRO 2003 Oct 1; 57(2 Suppl): S317-8 (poster and oral presentation).
41. Scarfone C, Lavelly WC, **Cmelak AJ**, Delbeke D, Martin WH, Billheimer D, Hallahan DE. Quantification of Molecular and Anatomical Target Contours of Head and Neck Cancer to Facilitate Image Guided Therapy During IMRT. Int J Radiat Oncol Biol Phys Proc ASTRO S300-1, 57(2) Suppl; 2003.
42. Lavelly WC, Scarfone C, **Cmelak AJ**, Martin WH, Price RR, Fitzpatrick JM, Hallahan DE. An Assessment of Accuracy and Determination of Target Volumes for Radiotherapy Treatment Planning in CT/PET Fusion Images of Patients with Head and Neck Cancer. Abstract submitted to Society of Molecular Imaging 5/23/03.
43. Scarfone C, Lavelly WC, **Cmelak AJ**, Martin WH, Price RR, Hallahan DE. Influence of Molecular Imaging Reconstruction Technique on Target Volumes for Planning Radiotherapy Treatments. Abstract submitted to Society of Molecular Imaging 5/23/03.

44. Reine TP, Murphy BA, Bhatt P, **Cmelak A**, Burkey B, Bayles S, Netterville J. Results of a Pilot Survey to Assess Supportive Care Needs in Head and Neck Cancer (HNC) Patients. J Clin Oncol Proc ASCO #2006, p. 498, 2003.
45. D'Haese PF, Niermann KJ, **Cmelak A**, Donnelly E, Duay V, Li R, Dawant BM. Neuroanatomical Automatic Segmentation in Brain Cancer Patients. Int J Radiat Oncol Biol Phys Proc ASTRO Oct 1; 57(2 Suppl): S205, 2003.
46. Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DHC, **Cmelak A**, Shenouda G, Schulsinger A, Fu K. Definitive Radiotherapy +/- Erythropoetin for Squamous Cell Carcinoma of the Head and Neck: Preliminary Report of RTOG 99-03. Int J Radiat Oncol Biol Phys 60(1): ASTRO 2004, abstr #5, S132, 2004.
47. D'Haese PF, Niermann KJ, **Cmelak AJ**, Pallavi J, Dawant B. Automatic Segmentation of the Human Spinal Canal Using an Intelligent Digital Atlas. Int J Radiat Oncol Biol Phys ASTRO Proc (Vol. 60, Issue 1 (Supplement), Pages S579-S580), 2004.
48. Stacy D, **Cmelak A**, Murphy BA. Radiosurgery Boost after Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma. Accepted for abstract and poster, HN Society, Wash DC, Aug 7, 2004.
49. Reine TP, Murphy BA, Netterville J, Burkey B, **Cmelak A**, Wells N, Scott V. Is A New Assessment Tool Necessary for Head and Neck Cancer Patients? J Clin Oncol Proc ASCO 23:#5571, p.504, 2004.
50. Murphy BA, Kish B, **Cmelak A**, Shyr Y, Netterville J, Burkey B, Chung W. Phase II Trial of Irontecan Plus Cisplatin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol Proc ASCO 23:#5580, p. 506, 2004.
51. Dwyer KA, Murphy BA, **Cmelak AJ**, Chung C, Burkey B, Netterville JL, Yarbrough W, McDowell MR. Predicting Psychosocial well-being in Head and Neck Cancer (HNC). J Clin Oncol Proc ASCO 23:#5538, p.495, 2004.
52. **Cmelak AJ**, Murphy BA, Raben D, Kane M, Weng E, Burkey B, Kish B, Song J, Netterville J. Early Results of a Phase II Multi-Institutional Trial of Chemoradiation (CR) Using Weekly Docetaxel (Doc) and Erythropoetin (Epo) for High-Risk Postoperative Head and Neck Cancer (HRPHNC) Patients. J Clin Oncol Proc ASCO23:#5552, p. 499, 2004.
53. Murphy BA, Wells NL, **Cmelak AJ**, Netterville JL, Burkey BB, Smith KZ. Reliability and Validity for the Vanderbilt Head and Neck Symptom Survey (VHNSS): A New Tool to Assess Symptom Burden in Patients Undergoing Chemoradiation. J Clin Oncol Proc ASCO 23:#5569, p.503, 2004.
54. P. D'Haese, K.J. Niermann, **AJ Cmelak**, P. Joshi, B. Dawant. Automatic Segmentation of the Human Spinal Canal Using an Intelligent Digital Atlas. Int J Radiat Oncol Biol Phys 60(1); ASTRO Proc abstr #2407, 2004.
55. B.A. Murphy, B. Shaktour, D. Raben, W. Reid, J. Netterville, B. Burkey, B. Kish, J. Song, M. Kane, **AJ Cmelak**. A Phase II Multi-Institutional Trial of Chemoradiation (CR) Using Weekly Docetaxel

(Doc) and Erythropoetin (Epo) for High-Risk Postoperative Head and Neck Cancer (HRHNC) Patients. J Clin Oncol Proc ASCO #5591 p. 522s, 2005.

56. **AJ Cmelak**, M.D., Sigui Li, Ph.D, Meredith A. Goldwasser, Sc.D., Barbara Murphy, M.D.¹, George L. Adams, M.D.³, Michael Cannon, Harlan Pinto, M.D., David Rosenthal, M.D, Arlene A. Forastiere, M.D. A Phase II Trial of Chemoradiation (CR) for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx (L) or Oropharynx (OP): A Trial of the Eastern Cooperative Oncology Group (E2399). J Clin Oncol ASCO Proc #5509, p. 502s, 2005.

57. D. Duggan, M. Beach, B.A. Murphy, M. Teng, D. Hallahan, B. Burkey, J. Netterville W. Yarbrough, P. Murphy, C.H. Chung, R. Young, L. Butler, W. Kirby, **A.J. Cmelak**. Intensity-Modulated Radiation Therapy (IMRT) with Concurrent Taxane-Based Chemotherapy for Locally-Advanced Head and Neck Cancer (LAHNC): Feasibility, Technique, and Toxicities. J Clin Oncol Proc ASCO #5536 p.509s, 2005.

58. Chung CH, Carter J, Ely K, Murphy BA, Burkey BB, Netterville JL, Levy S, **Cmelak AJ**, Slebos WG, Yarbrough WG. Gene Expression Analysis of Head and Neck Squamous Cell Carcinoma Using Formalin-Fixed Paraffin Embedded Tissue. J Clin Oncol Proc ASCO #5537, p. 509s, 2005.

59. Kumar P, Robbins KT, Harris J, McCulloch T, **Cmelak A**, Sofferman R, Levine P, Fu K. Mature Results of Radiation Therapy Oncology Group (RTOG) Trial 9615 Using Intra-Arterial Cisplatin (IA-P) and Concurrent Radiation therapy (RT) for Stage IV-T4 Head/Neck (H/N) Squamous Cell Carcinoma (SCCa). J Clin Oncol Proc ASCO #5579 p. 519s, JCO 2005.

60. Niermann KJ, Joshi P, d'Haese P, Duggan DM, **Cmelak AJ**, Dawant BM. Automated Intracranial Contouring for Brain Cancer Patients: Treatment Plan Validation. Int J Radiat Oncol Biol Phys, Proc ASTRO, #2335, S369, 2005.

61. Murphy BA, Smith K, **Cmelak A**, Forastiere A. Swallowing Function for Patients Treated on E2399: A Phase II Trial of Function Preservation with Induction Paclitaxel/Carboplatin Followed by Radiation Plus Weekly Paclitaxel. J Clin Oncol Proc ASCO 286s: #5524, 2006.

62. **Cmelak AJ**, Li S, Murphy B, Burkey B, Adams GL, Cannon M, Pinto H, Rosenthal DI, Ridge JA, Forastiere AA. Locally Advanced Resectable Larynx (L) or Oropharynx (OP) Cancer: Updated Results of Organ Preservation Trial E2399. J Clin Oncol: Proc ASCO 286s: #5527, 2006.

63. Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S, Kish J, **Cmelak A**, Kim H, Fu K. Long-Term Follow-up of a Phase III Intergroup Trial of Surgery Followed by Radiotherapy Vs. Radiochemotherapy for Resectable High-Risk Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys November 1, Vol. 66, Issue 3 (Supplement), Pages S14-S15, 2006.

64. Fakhry C, Westra W, Li S, **Cmelak A**, Adams GL, Pinto H, Forastiere AA, Gillison ML. [PS 19-1] Improved Treatment Response and Prognosis of Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) in a Prospective, Multi-Center Phase II Clinical Trial. International Papillomavirus Society, Prague CZ Sept 2006.

65. Fakhry C, Westra W, Li S, **Cmelak A**, Ridge J, Pinto H, Forastiere A, Gillison M. Prognostic Significance of Human Papillomavirus (HPV) tumor status for patients with head and Neck Squamous Cell Carcinoma (HNSCC) in a Prospective Multi-Center Phase II clinical Trial. Proc ASCO; 299s, #6000, 2007.
66. Gilbert J, **Cmelak A**, Burkey B, Sinard R, Yarbrough W, Netterville J, Paty V, Chung C, Hudson T, Murphy B. Phase II Trial of Irinotecan (Ir) Plus Cisplatin (CDDP) in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck (SCCHN). Proc ASCO 309s; #6041, 2007.
65. Diaz R, Thorpe SW, Musphy BA, Kirby W, Burkey BB, Chung CH, Shaktour B, Murphy P, Beach M, **Cmelak AJ**. Intensity-Modulated Radiation Therapy (IMRT) with concurrent Taxane-Based Chemotherapy for Locally-Advanced Head and Neck Cancer (LAHNC): Toxicities and Efficacy. Int J Radiat Oncol Biol Phys 69(3): Supplement 1, 1 November 2007, Page S464.
66. Ding GX, Duggan DM, Lu B, Hallahan DE, **Cmelak A**, Malcolm A, Coffey CW. The Need for Accurate Dose Calculation Algorithms With Inhomogeneity Corrections in Treatment Planning for a Small Lung Tumor Treatment. Int Journ Rad Oncol Biol Phys 69(3): Supplement 1, 1 November 2007, Pages S697-S698.
67. Gilbert J, Haman K, Yarbrough WG, Dietrich MS, Chung CH, A, **Cmelak AJ**, Pham M, Muldowney N, Blakely RD, Murphy BA. Head and Neck Cancer (HNC), Depression and Genetic Polymorphism. Proc ASCO #6017, J Clin Oncol 26 (15S), 320s; May 2008.
68. Murphy BA, Dietrich MS, **Cmelak AJ**, Burtness BA, Forasteire AA. E2399: Correlation of Objective and Self Report Measures of Swallowing Function After Concurrent Chemoradiation (CCR) for Head and Neck Cancer (HNC). Proc ASCO #6022, J Clin Oncol 26 (15S), 320s; May 2008.
69. E2399: Correlation of objective and self report measures of swallowing function after concurrent chemoradiation (CCR) for head and neck cancer (HNC). Proc ASCO #6022, 320s: J Clin Oncol 26(15S), May 2008.
69. Chung CH, Aulino J, Parker J, Cmelak AJ, Netterville J, Burkey B, Sinard R, Yarbrough WG, Murphy BA, Gilbert J. Gene Expression Profile of Penetrexed and Oxaliplatin Response in a Phase II Induction Trial in Locally Advanced Head and Neck Squamous Cell Carcinoma. Proc ASCO #6039; J Clin Oncol 26 (15S), 325s; May 2008.
70. Gilbert J, Aulino J, Parker J, **Cmelak A**, Netterville J, Burkey B, Sinard R, Yarbrough WG, Murphy BA, Chung CH. Gene Expression Profile of Pemetrexed and Oxaliplatin Response in a Phase III Induction trial in Locally Advanced head and Neck Squamous Cell Carcinoma. Proc ASCO #.
71. 71. Diaz R, Jaboin, Stinson S, Gilbert J, Chung CH, Murphy BA, Burkey B, Netterville J, Yarbrough WG, Murphy PB, **Cmelak AJ**. Hypothyroidism as a Consequence of Intensity-Modulated Radiation Therapy (IMRT) with Concurrent Taxane-Based Chemotherapy for Locally-Advanced Head and Neck Cancer (LAHNC). Proc ASCO #6048; J Clin Oncol 26(15S), 328s; May 2008.

BOOK CHAPTERS:

1. Demanes DJ, Rodriguez RR, Hsu ICJ, **Cmelak AJ**, Eulau SM: "Efficacy of Interstitial HDR Brachytherapy in Gynaecological Malignancies." In: New Developments in Interstitial Remote Controlled Brachytherapy Vol 2, W. Zuckschwerdt Verlag, N. Zamboglou (ed.), New York, N.Y., 1997.
2. Demanes DJ; Rodriguez RR; Hsu ICJ; **Cmelak AJ**; Brachytherapy - Oncological Seminars on Locoregional Therapy (Vol 2). New York: Zuckschwerdt, 1997
3. **Cmelak AJ**, Roberts J, Meranze SG, Johnson DH: "Superior Vena Cava Syndrome." In: Clinical Oncology (second edition), Chapter 36. Abeloff, MD; Armitage, JO; Lichter, AS; Neiderhuber, JE (eds), Churchill Livingstone, 1999.
4. Petty MM, **Cmelak AJ**, Johnson MD, Sinatra R, Jennings M; "Retinoblastoma". In: Textbook of Uncommon Cancer (second edition). Ragavan D, Brecher ML, Johnson DA, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley and Sons, 1999.
5. Moots P, Jennings M, **Cmelak AJ**, Johnson M. "Glioma and Other Neuroepithelial Neoplasms." In: Textbook of Uncommon Cancer (2nd edition). Ragavan D, Brecher ML, Johnson DA, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley and Sons, 1999.
6. Murphy BA, **Cmelak A**, Bayles S, Dowling E, Billante CR. "Palliative Issues in the Care of Patients with Cancer of the Head and Neck." In: The Management of Advanced Cancer. Cherney N, et al. (eds.) Oxford University Press.
7. **Cmelak AJ**. Radiotherapy in the Management of Cushing's Disease." In: Cushing's Syndrome, Blevins LS (ed), Kluwer Academic Publishers (Norwell MA), pp. 301-321, 2002.
8. Scarfone C, Patton JA, **Cmelak AJ**, Sandler MP. "Gamma Camera-Based PET Inverse Treatment Planning for Head and Neck Cancer Using Hybrid Imaging Instrumentation and IMRT." In: The Scintillating Future of Nuclear Medicine. Elsevier Publishing, International Congress Series, pp.31-40, 2001.
9. **Cmelak AJ**, Scarfone C. "Radiation Therapy for Head and Neck Cancer." Atlas of Cancer. M Markum (ed.), Current Medicine, Inc. Lippincott Williams & Wilkins, Phila, PA, pp.15-27, 2003.
10. Laskin J, **Cmelak AJ**, Roberts J, Meranze SG, Johnson DH: "Superior Vena Cava Syndrome." In: Clinical Oncology (third edition), Chapt 55. Abeloff, MD; Armitage, JO; Lichter, AS; Neiderhuber, JE (eds), Churchill Livingstone, 2006.
11. Murphy BA, **Cmelak A**, Bayles S, Dowling E, Billante CR. "Head and Neck Cancer." Palliative Medicine (3rd Ed), Chapter 8.11, pp.858-872, Oxford University Press, 2003.
12. Laskin J, **Cmelak AJ**, Roberts J, Meranze SG, Johnson DH: "Superior Vena Cava Syndrome." In: Clinical Oncology (third edition), Chapter 54. Abeloff, MD; Armitage, JO; Lichter, AS; Neiderhuber, JE (eds), Churchill Livingstone, 2004.

13. Moots P, Johnson M, Jennings M, **Cmelak AJ**. "Glioma and Other Neuroepithelial Neoplasms." In: Textbook of Uncommon Cancer (third edition). Ragavan D, Brecher ML, Johnson DA, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley and Sons, Chap 62, p. 674, 2006.
14. Murphy BA, Aulino J, Chung C, Ely K, Sinard R, **Cmelak A**. "Esthesioneuroblastoma." In: Textbook of Uncommon Cancer (third edition). Ragavan D, Brecher ML, Johnson DA, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley and Sons, Chap 9, p. 133, 2006
15. Murphy BA, **Cmelak A**. "Chemoradiation Therapy: The Evolving Role in Head and Neck Cancer and Its Application to Oral Cavity Tumors." Oral and Maxillofacial Surgery Clinics of North America. Oral Cancer. Reddy SP, Haug RH (eds), WB Saunders Inc, Volume 18, #4, pp. 605-614, Nov 2006.
16. **Cmelak AJ**, Duggan D. "Radiation Therapy for Head and Neck Cancer (2nd Edition)." Atlas of Cancer, 2nd Edition. M. Markum (ed.), Current Medicine Group, LLC. Springer Science+Business Media, LLC. 2008.
17. Laskin J, **Cmelak AJ**, Lambright E, Meranze SG, Johnson DH: "Superior Vena Cava Syndrome." In: Clinical Oncology (fourth edition). Abeloff, MD; Armitage, JO; Lichter, AS; Neiderhuber, JE (eds), Churchill Livingstone, 2007 (in preparation).
18. Murphy BA, **Cmelak A**, Sinard R, Ridner S, Flores AM, Gilbert J. "Palliative Issues in the Care of Patients with Cancer of the Head and Neck." The Management of Advanced Cancer (2nd edition). Cherney N, et al. (eds.) Oxford University Press. In preparation .
19. Yang ES, Murphy BM, Chung CH, Nettekville JL, Burkey BB, Gilbert J, Yarbrough W, Robert Sinard R, **Cmelak AJ**. Evolution of Clinical Trials in Head and Neck Cancer: The Vanderbilt University Medical Center Experience. Submitted to Current Research in Cancer.

INVITED PRESENTATIONS:

"Radiosurgery for Skull-Base Malignancies and Nasopharyngeal Carcinoma." Stanford Oncology Symposium, March 10, 1994, Stanford, CA.

"Long Term Survival with Whole Abdominal Pelvic Irradiation in Platinum Refractory Ovarian Cancer." ASTRO, October 10, 1995, Miami, FL.

"Radiosurgery for Skull-Base Malignancies and Nasopharyngeal Carcinoma." ASTRO, October 28, 1996, Los Angeles, CA.

"Long Term Survival with Whole Abdominal Pelvic Irradiation in Platinum Refractory Ovarian Cancer." Stanford Oncology Symposium, February 8, 1996, Stanford CA.

"Combination Therapy for Head and Neck Carcinoma." Seventh Annual Cancer Conference, St. Mary's Hospital, Huntington, West Virginia, September 19, 1997.

“Combined Modality Therapy for Locoregionally-Advanced Head and Neck Cancer. Second Bi-Annual Symposium on Concomitant Chemoradiotherapy. Nashville, Tennessee. September 21, 1998.

“New Radiotherapy Techniques in the Treatment of Head and Neck Carcinoma.” Southern Academy of Head and Neck Surgeons, Chattanooga TN, Aug 7, 1998.

“Combination Therapy for Locoregionally-Advanced Carcinoma of the Head and Neck.” Grand Rounds, Mt. Diablo Hospital, Concord, CA., Oct. 19, 1998.

“Chemoirradiation for Head and Neck Cancer - Where Are We Going?”- Oncology Grand Rounds, Michigan State University, November 15, 1998.

“Multimodality Treatment of Head and Neck Cancer.” St Luke’s Hospital and Mountain States Tumor Institute, Boise ID, Jan 21, 1999.

Combination Chemoradiation for Locally-Advanced Cancer of the Head and Neck.” Grand Rounds, Hawaii Society of Clinical Oncology, March 8, 1999.

“New Directions in Head and Neck Cancer Treatment.” Grand Rounds, Monterrey Community Medical Center, March 10, 1999.

“Combined Modality Therapy for Head and Neck Cancer – New Directions.” Central California ENT Association, July 15, 1999.

“Head and Neck Cancer Symposium.” Mercy Medical Center, Redding, CA July 16, 1999.

“Stereotactic Radiosurgery for Medically-Intractable Mesial Temporal Lobe Epilepsy.” Radiological Society of North America (RSNA), November 30, 1999.

“New Nonsurgical Therapies for Head and Neck Cancer.” Mercy Medical Center, Fresno CA. July 18, 2000.

“Trimodality Therapy for Locally Advanced Head and Neck Cancer.” Sacramento, CA. July 19, 2000.

“Head and Neck Cancer: Where have we been, and where we are going.” MeHarry Medical School, Nashville, TN. September 2000.

“Past, Present, and Future: Progress in the Treatment of Head and Neck Cancer.” Ball State Memorial Hospital Grand Rounds, Muncie, IN. October 1, 2000.

“Anemia in the Oncology Patient.” Grand Rounds, Hardin Memorial Hospital, Elizabethtown, KY. April 18, 2001.

“Recombinant Human Erythropoietin (r-HuEPO) Corrects Anemia and Prevents Transfusion During Induction and Concurrent Chemotherapy During Head and Neck Cancer (HNC) Treatment.” ECCO 11, Lisbon, Portugal Oct 23, 2001.

“Radiation Schedules With Synchronous Chemotherapy For Carcinoma of the Lung.” Chemotherapy/Radiation Combination Therapy in the Treatment of Solid Tumors: Advances, Controversies and Future Directions. Baveno, Italy. May 4, 2002.

“Radiation Therapy and Radiosurgery for Brain Metastases.” Trimodality Conference on Brain Metastases, Nashville TN. Oct 7, 2002.

“Anemia in the Cancer Patient: Impact on Quality of Life and Treatment Outcome.” Little Rock AR, Feb 27, 2003.

“Management of Anemia in the Cancer Patient.” West Clinic, Memphis, TN. March 24, 2003.

“Cognition Impairment in the Cancer Patient – Possible Causes and Treatment.” St. Francis Hospital Oncology Associates, May 20, 2003.

“Management of Radiation and Chemoradiation Induced Anemia.” St. Dominic-Jackson Memorial Hospital Cancer Conference, Jackson MS, June 17, 2003.

“Anemia in the Oncology Patient: Etiology and Treatment Options.” Memphis, TN, Aug 18, 2003.

“Anemia Management in Cancer Patients.” Jeff Anderson Regional Cancer Center, Meridian, MS, Aug 20, 2003.

“Preservation of Cognitive Function in Cancer Patients: Anemia Management and Neuroprotection.” Cincinnati, OH October 22, 2003.

“Peptide-Guided Drug Delivery to Radiation-Induced Targets in Tumor Blood Vessels.” ASTRO, October 22, 2003.

“Breast Cancer Radiotherapy: the Past, Present, and Future.” Williamson Medical Center Annual Symposium, October 29, 2003.

“Management of Anemia and Neuroprotection During Chemotherapy and Radiotherapy.” Tampa, Florida January 21, 2004.

“Neuroprotection During Cancer Therapy.” Jackson-Madison County Hospital Grand Rounds, March 2, 2004.

“The Role of Radiosurgery in Managing Patients With Brain Tumors.” Vanderbilt University’s Brain Tumor Therapy – State of the Art’ symposium, May 1, 2004.

“Preservation of Cognitive Function in Cancer Patients: Anemia Management and Neuroprotection.” Kansas City University Medical Center, May 11, 2004.

“Clinical Update in Anemia Management: Hematologic Malignancies.” U. Tennessee Cancer Institute, October 11, 2004.

- “Anemia in the Oncology Patient.” Kaiser Permanente Grand Rounds, Fairfax, VA October 25, 2004.
- “Management of Anemia in Patients with Hematologic Malignancies.” Tempe, AZ November 17, 2004.
- “IGRT and Extracranial Radiosurgery: Clinical Issues.” Nashville IGRT Symposium, Nashville TN March 17, 2005.
- “Head and Neck Cancer: Radioprotection or Sensitization from Erythropoetic Agents.” University of Louisville, April 1, 2005.
- “Anemia in the Cancer Patient: Treatment Issues.” McKinney Cancer Center, June 17, 2005.
- “Cancer Treatment and Anemia.” ASH, Atlanta GA, Dec 11, 2005
- “Appropriate Use of Erythropoietic Therapy for Chemotherapy-Induced Anemia”. Grand Rounds, McKinney, TX, Jan 20, 2006.
- “Treatment of Anemic Cancer Patients.” 8th Annual Evolving Science of Oncology and Blood/Marrow Transplantation. Scottsdale, AZ. April 4, 2006.
- “Cetuximab in the Treatment of Head and Neck Cancer.” Maury Regional Cancer Center, May 24, 2006.
- “Head and Neck Cancer: Cetuximab for Locally Advanced and Recurrent Patients.” Crossville Regional Cancer Center, May 25, 2006.
- “Locally Advanced Resectable Larynx (L) or Oropharynx (OP) Cancer: Updated Results of Organ Preservation Trial E2399.” Poster presentation and discussion Atlanta ASCO 2006.
- “EGFR Inhibition for Locally-Advanced and Recurrent Head and Neck Cancer.” Paducah, KY June 12, 2006.
- “Her-1/EGFR Blockade with Head and Neck Radiotherapy: A New Standard of Care?” Knoxville, TN. June 20, 2006.
- “Radiotherapy With and Without EGFR Inhibition.” University of Louisville, July 25, 2006.
- “New Treatments in Head and Neck Cancer.” Jacksonville, FL, Oct 10, 2006.
- “Targeted Therapies in Locally Advanced Cancer of the Head and Neck.” St John's Cancer Center, Springfield, MO, Oct 12, 2006.
- “EGFR inhibition in Head and Neck Cancer: A Replacment or Alternative to Chemoradiation?” CROA - Chat Regional Oncology Association, Oct 19, 2006.
- “Locally-Advanced and Recurrent Head and Neck Cancer.” Virginia Baptist Hospital, Lynchburg VA. Nov 7, 2006.

“Anemia in the Oncology Patient – Incidence and Impact.” Medical University of South Carolina, Dec 1, 2006.

“Intensity-Modulated Radiation Therapy (IMRT) and Chemoradiation for Head and Neck Cancer.” Amgen Symposium, Thousand Oaks, CA. Feb 23, 2007.

“EGFR Inhibition for Locally Advanced and Metastatic Head and Neck Cancer.” West Michigan Cancer Center, Oct 11, 2007.

“New Treatment Paradigms in Head and Neck Cancer.” St. John’s Cancer Center, Oxnard CA, Nov , 2007.

“Evolving Standards of Care: Combining Surgery, Radiation, and Chemotherapy in Locally Advanced Head and Neck Cancer.” USC Kenneth Norris Cancer Center, Los Angeles, CA. Nov 2, 2007.

“Current Approaches to Radiation Therapy.” Third Annual Multidisciplinary Symposium on Head and Neck Cancer. Philadelphia, PA. Dec 1, 2007.